ATE364315T1 - Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung - Google Patents

Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung

Info

Publication number: ATE364315T1
Authority: AT; Austria
Prior art keywords: tgfalpha; disclosed; tgf; functional fragments; patients undergoing
Prior art date: 1999-04-26

Application number

AT00928576T

Other languages

English (en)

Inventor

Daniel Twardzik

Stefan Paskell

Thomas Felker

Original Assignee

Applied Protein Sciences Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-26

Filing date

2000-04-26

Publication date

2007-07-15

1999-04-26 Priority claimed from US09/299,473 external-priority patent/US20020099008A1/en

2000-04-26 Application filed by Applied Protein Sciences Llc filed Critical Applied Protein Sciences Llc

2007-07-15 Application granted granted Critical

2007-07-15 Publication of ATE364315T1 publication Critical patent/ATE364315T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Oncology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Zoology (AREA)
Physical Education & Sports Medicine (AREA)
Addiction (AREA)
Psychology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)

AT00928576T 1999-04-26 2000-04-26 Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung ATE364315T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/299,473 US20020099008A1 (en)	1999-04-26	1999-04-26	Method for stimulating hematopoiesis using tgf-alpha
US09/459,813 US6764683B1 (en)	1999-04-26	1999-12-13	Loop peptide and TGFα for stimulating stem cell proliferation and migration

Publications (1)

Publication Number	Publication Date
ATE364315T1 true ATE364315T1 (de)	2007-07-15

Family

ID=26971235

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00928576T ATE364315T1 (de)	1999-04-26	2000-04-26	Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung

Country Status (8)

Country	Link
US (4)	US6486122B1 (de)
EP (1)	EP1176870B1 (de)
JP (1)	JP2002543096A (de)
AT (1)	ATE364315T1 (de)
AU (1)	AU4679300A (de)
CA (1)	CA2371241A1 (de)
DE (1)	DE60035192T2 (de)
WO (1)	WO2000065028A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010007657A1 (en) *	1997-08-04	2001-07-12	Reid James Steven	Compositions and methods for manipulating glial progenitor cells and treating neurological deficits
US7795202B2 (en) *	1997-08-04	2010-09-14	Neurorepair, Inc.	Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a)
JP2001511456A (ja)	1997-08-04	2001-08-14	ザリージェンツオブザユニバーシティオブカリフォルニア	神経学的欠損を治療する方法
JP2002543841A (ja) *	1999-05-17	2002-12-24	バイオファームゲゼルシャフトツアバイオテクノロジシェンエントヴィックルングウントツムフェルトリーブフォンファルマカエムベーハー	ＴＧＦ−βスーパーファミリーの新規のメンバーであるＧＤＦ―１５の神経保護特性
AU6920800A (en) *	1999-08-19	2001-03-13	Stem Cell Pharmaceuticals, Inc.	Tgf-alpha polypeptides, functional fragments and methods of use therefor
US20020193301A1 (en) *	1999-08-19	2002-12-19	Stem Cell Pharmaceuticals, Inc.	TGF-alpha polypeptides, functional fragments and methods of use therefor
US7838292B1 (en) *	2001-03-29	2010-11-23	University Of Louisville Research Foundation, Inc.	Methods for obtaining adult human olfactory progenitor cells
US20070054851A1 (en) *	2005-05-27	2007-03-08	Junyu Lin	Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
US20070031373A1 (en) *	2005-08-04	2007-02-08	Carlos Lopez	Reversal of Adult Onset Disorders with Granulocyte-Colony Stimulating Factors
TW201500549A (zh)	2013-06-19	2015-01-01	Univ Taipei Medical	促進幹細胞方向性移動之方法及裝置
WO2016057900A1 (en) *	2014-10-10	2016-04-14	Neurorepair, Inc.	Novel tgf-alpha mutant proteins

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3382562D1 (de)	1982-09-24	1992-06-25	Us Health	Wiederherstellung von gewebe bei tieren.
US5240912A (en)	1983-05-09	1993-08-31	Todaro George J	Transforming growth factor (TGF) peptides
JPS6034997A (ja)	1983-05-09	1985-02-22	ジヨージ、ジヨセフ、トダロ	生物学的活性ポリペプチド類
US4863899A (en)	1983-05-09	1989-09-05	Todaro George J	Biologically active polypeptides
DE3587022T2 (de)	1984-02-17	1993-06-17	Genentech Inc	Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
US4749683A (en)	1985-01-25	1988-06-07	President And Fellows Of Harvard College	Inhibition of gastric acid secretion with alpha-transforming growth factor
AU5249786A (en) *	1985-01-29	1986-08-07	Oncogen	Wound healing compositions
US4686283A (en) *	1985-04-16	1987-08-11	Syntex (U.S.A.) Inc.	Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis
CA1275922C (en)	1985-11-28	1990-11-06	Harunobu Amagase	Treatment of cancer
DK354487A (da) *	1986-07-11	1988-01-12	Noboru Yanaihara	Oncogen-relaterede peptider
US4874746A (en)	1987-12-22	1989-10-17	Institute Of Molecular Biology, Inc.	Wound headling composition of TGF-alpha and PDGF
US5658894A (en)	1989-04-23	1997-08-19	The Trustees Of The University Of Pennsylvania	Compositions for inhibiting restenosis
US5102870A (en) *	1989-04-14	1992-04-07	Schering Ag	Treatment and prevention of oral mucositis with growth factors
US5182261A (en) *	1989-07-13	1993-01-26	The Rockefeller University	Modified transforming growth factor alpha oligopeptides and pharmaceutical compositions thereof
IL98528A0 (en) *	1990-06-21	1992-07-15	Merck & Co Inc	Pharmaceutical compositions containing hybrid for killing bladder cancer cells
AUPN271295A0 (en) *	1995-05-02	1995-05-25	Gropep Pty Ltd	Method of treatment
US5229493A (en)	1990-10-26	1993-07-20	Children's Medical Center Corporation	Smooth muscle mitogen
US5886141A (en)	1990-10-26	1999-03-23	Takeda Chemical Industries, Ltd.	Smooth muscle mitogen peptides and DNA coding therefor
JPH04352800A (ja)	1990-10-26	1992-12-07	Childrens Medical Center Corp:The	平滑筋分裂促進因子
US5604202A (en) *	1990-11-13	1997-02-18	Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University	Use of NGF growth factors to treat drug-induced neuropathy
CA2112473A1 (en) *	1991-07-05	1993-01-21	Patricia A. Bacha	Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis
US5981165A (en)	1991-07-08	1999-11-09	Neurospheres Holdings Ltd.	In vitro induction of dopaminergic cells
US5851832A (en)	1991-07-08	1998-12-22	Neurospheres, Ltd.	In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5750376A (en)	1991-07-08	1998-05-12	Neurospheres Holdings Ltd.	In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5980885A (en)	1991-07-08	1999-11-09	Neurospheres Holdings Ltd.	Growth factor-induced proliferation of neural precursor cells in vivo
US6071889A (en)	1991-07-08	2000-06-06	Neurospheres Holdings Ltd.	In vivo genetic modification of growth factor-responsive neural precursor cells
AU3062392A (en) *	1991-11-04	1993-06-07	Novo Nordisk A/S	Pdgf gel formulation
US6558952B1 (en)	1992-12-14	2003-05-06	Waratah Pharmaceuticals, Inc.	Treatment for diabetes
US5885956A (en)	1992-12-14	1999-03-23	Research Triangle Pharmaceuticals	Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
FI953569A7 (fi)	1993-01-29	1995-09-25	Neurospheres Ltd	Neuraalisten kantasolujen geneettinen modifikaatio
US5633147A (en) *	1994-03-08	1997-05-27	Human Genome Sciences, Inc.	Transforming growth factor αH1
GB9500660D0 (en) *	1995-01-13	1995-03-08	Secr Defence	Growth factor anologs
US5840687A (en) *	1995-02-02	1998-11-24	Schering Aktiengesellschaft	Modified ligands for receptor tyrosine kinases
US6232288B1 (en)	1995-11-09	2001-05-15	Takeda Chemical Industries, Ltd.	Composition for improving pancreatic function
EP0873360A4 (de)	1996-01-04	2000-06-21	Human Genome Sciences Inc	Transformierender wachstumsfaktor alpha hiii
US5814308A (en)	1996-03-26	1998-09-29	Zhang; Ke	Methods for the treatment of gastrointestinal tract disorders
EP0941109A1 (de)	1996-11-15	1999-09-15	Neurospheres Holdings Ltd.	Vorbehandlung mit wachstumsfaktoren zur schützen gegen schädigung des zns
JPH10158188A (ja) *	1996-11-29	1998-06-16	Senju Pharmaceut Co Ltd	角膜治療用組成物
AU5261898A (en)	1996-12-04	1998-06-29	Abbot F. Clark	Tgfalpha for the treatment of ocular hypertension and glaucoma
US6114307A (en)	1996-12-16	2000-09-05	Zymogenetics, Inc.	Methods for stimulating pancreatic islet cell regeneration
JP2001511456A (ja) *	1997-08-04	2001-08-14	ザリージェンツオブザユニバーシティオブカリフォルニア	神経学的欠損を治療する方法
WO2000047720A2 (en)	1999-02-10	2000-08-17	Curis, Inc.	Pancreatic progenitor cells, methods and uses related thereto
US6037357A (en) *	1999-04-21	2000-03-14	Unitech Pharmaceuticals, Inc.	N-benzoyl-α-alkylated azatyrosines as anticancer agents
US20020193301A1 (en) *	1999-08-19	2002-12-19	Stem Cell Pharmaceuticals, Inc.	TGF-alpha polypeptides, functional fragments and methods of use therefor
AU6920800A (en) *	1999-08-19	2001-03-13	Stem Cell Pharmaceuticals, Inc.	Tgf-alpha polypeptides, functional fragments and methods of use therefor
US20020077291A1 (en) *	2000-09-22	2002-06-20	Alan Upshall	Method of treatment of tumors using transforming growth factor-alpha

2000
- 2000-04-26 AT AT00928576T patent/ATE364315T1/de not_active IP Right Cessation
- 2000-04-26 WO PCT/US2000/011564 patent/WO2000065028A2/en not_active Ceased
- 2000-04-26 US US09/559,248 patent/US6486122B1/en not_active Expired - Fee Related
- 2000-04-26 JP JP2000614365A patent/JP2002543096A/ja active Pending
- 2000-04-26 EP EP00928576A patent/EP1176870B1/de not_active Expired - Lifetime
- 2000-04-26 DE DE60035192T patent/DE60035192T2/de not_active Expired - Lifetime
- 2000-04-26 CA CA002371241A patent/CA2371241A1/en not_active Abandoned
- 2000-04-26 AU AU46793/00A patent/AU4679300A/en not_active Abandoned
2001
- 2001-09-12 US US09/955,581 patent/US20020169131A1/en not_active Abandoned
2004
- 2004-07-16 US US10/893,172 patent/US7365172B2/en not_active Expired - Fee Related
2007
- 2007-10-31 US US11/932,563 patent/US20090068139A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2371241A1 (en)	2000-11-02
AU4679300A (en)	2000-11-10
US6486122B1 (en)	2002-11-26
WO2000065028A9 (en)	2002-03-14
US20060105957A1 (en)	2006-05-18
WO2000065028A2 (en)	2000-11-02
DE60035192T2 (de)	2008-02-14
EP1176870A2 (de)	2002-02-06
DE60035192D1 (de)	2007-07-26
EP1176870B1 (de)	2007-06-13
WO2000065028A3 (en)	2001-05-03
EP1176870A4 (de)	2002-07-31
US20090068139A1 (en)	2009-03-12
US7365172B2 (en)	2008-04-29
JP2002543096A (ja)	2002-12-17
US20020169131A1 (en)	2002-11-14

Legal Events

Date	Code	Title	Description
2007-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
CY1118849T1 (el)	2018-01-10	Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
CY1121113T1 (el)	2019-07-10	Θεραπεια της νοσου ρομρε
MA28418B1 (fr)	2007-02-01	Anticorps liant un recepteur de l'interleucine 4
EP1545613A4 (de)	2008-10-15	Arzneimittel-kononjugate und ihre verwendung zur behandlung von krebs, einer autoimmunkranheit oder einer infektionskrankheit
NO20015584L (no)	2002-01-03	Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
IS7431A (is)	2004-08-31	Samrunaefnasambönd lyfja eða frumudrepandi efna og líffræðilega virkra peptíða
TR200103560T2 (tr)	2002-09-23	Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
NZ516381A (en)	2004-03-26	Lung tumor proteins in the therapy and diagnosis of lung cancer
WO2003049684A3 (en)	2004-02-26	Pseudo-antibody constructs
DK0910647T3 (da)	2008-07-21	Human DNase i hyperaktive varianter
PT698108E (pt)	2002-04-29	Vectores adenovirais de origem animal e utilizacao em terapia genica
DE69615561D1 (de)	2001-10-31	Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
NO20053999D0 (no)	2005-08-29	Survivin-avledede peptider og bruken av dem
TR200202231T2 (tr)	2002-11-21	Amiloidojenik hastalığın önlenmesi ve tedavisi
TR200301846T2 (tr)	2006-10-26	Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
BR0111182A (pt)	2004-02-25	Peptìdeos neuroprotetores
DE60035192D1 (de)	2007-07-26	Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
BR9808509A (pt)	2001-09-18	Composições e métodos para o tratamento e diagnóstico do câncer de mama
DK1007566T3 (da)	2007-01-02	Terapeutisk anvendelse af SMR1-protein og aktive derivater deraf
EP1532162A4 (de)	2006-05-03	Humanisierter anti-tag-72 cc49 zur diagnose und therapie humaner tumore
AU6987696A (en)	1997-03-27	The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
KR100488038B1 (ko)	2005-05-09	기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
DE60036199D1 (de)	2007-10-11	Proteaseresistente flint-analoge
AP2034A (en)	2009-08-28	Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.
MXPA03009138A (es)	2004-02-18	Produccion de anticuerpos monoespecificos policlonales, contra variantes del receptor activador del plasminogeno de tipo uroquinasa (upar) del4, del5 y del4+5 y su uso para propositos de diagnostico y terapeutico.